A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

266 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A clinical study to evaluate the efficacy and safety of MK0633 in patients with Chronic Obstructive Pulmonary Disease (COPD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)

NCT00132730

Lung Diseases Pulmonary Disease, Chronic Obstructive

TERMINATED PHASE2

A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)

NCT00482235

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE2

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

NCT06154837

Pulmonary Disease, Chronic Obstructive

RECRUITING PHASE1

An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01867762

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE2

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT02536508

COPD

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease (COPD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

MK0633

Group Type EXPERIMENTAL

MK633

Intervention Type DRUG

MK0633 100mg capsules qd for a 12-wk treatment period.

2

Placebo

Group Type PLACEBO_COMPARATOR

Comparator: Placebo (unspecified)

Intervention Type DRUG

MK0633 100mg Pbo capsules for a 12-wk treatment period

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK633

MK0633 100mg capsules qd for a 12-wk treatment period.

Intervention Type DRUG

Comparator: Placebo (unspecified)

MK0633 100mg Pbo capsules for a 12-wk treatment period

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented COPD defined by clinical history and spirometry, with symptoms including dyspnea, wheezing, chest tightness, cough, sputum production, or nocturnal awakening
* Male or postmenopausal females 40 -75 years of age

Exclusion Criteria

* Impaired renal function
* History of chronic liver disease or persistent liver function test (LFT) abnormalities
* History of recent cardiovascular clinical event
* Evidence of another clinically significant, active pulmonary disorder such as bronchiectasis or asthma

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No